UO di Oncologia Ematologia, Azienda Ospedaliero Universitaria di Ferrara
Welcome,         Profile    Billing    Logout  
 10 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Frassoldati, Antonio
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
12/23
12/23
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Calendar Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer
Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
LEPRE, NCT05601700 / 2020-003066-39: Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer ( Trial)

Recruiting
3
132
Europe
Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Humanitas Hospital, Italy
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
09/29
09/29
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting
2
49
Europe
Atezolizumab,Paclitaxel, Carboplatin
Consorzio Oncotech
Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
07/24
07/24
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
BIO-META, NCT02284581: Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments

Recruiting
N/A
10000
Europe
Consorzio Oncotech
Metastatic Breast Cancer
06/23
12/25
PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32
Todeschini
No trials found

Download Options